Abstract
Background There is insufficient evidence to support clinical decision-making for oncology patients diagnosed with COVID-19 due to the lack of large studies.
Methods We used data from a large UK Cancer Centre to assess demographic/clinical characteristics of 106 cancer patients with a confirmed COVID-19 diagnosis between 29 February-15 April 2020. Logistic/Cox proportional hazards models were used to identify which demographic and/or clinical characteristics were associated with COVID-19 severity/death.
Results 87 (82%) presented with mild/moderate COVID-19 and 19(18%) with severe disease. Age, sex, ethnicity, SES, and current cancer treatment were not associated with COVID-19 severity. Initial diagnosis of cancer >24m before COVID-19 (OR:3.01 (95%CI: 1.02-8.58)), presenting with fever, dyspnoea, gastro-intestinal symptoms, or higher levels of CRP and ferritin were linked with greater COVID-19 severity. During median follow-up of 17.5d, 14 patients had died of COVID-19(13%).
Conclusions Low SES, hypertension and non-malignant lung disease were common in cancer patients with COVID-19. A longer-established diagnosis of cancer was associated with increasing severity of infection, possibly reflecting effects of more advanced malignant disease on impact of this infection. Advanced age and comorbidities may be associated with an increased risk of COVID-19-related death in cancer patients, as has been reported for general populations without cancer.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Data was collected from Guy's Cancer Cohort which is a research ethics committee approved research database (Reference number: 18/NW/0297) of all routinely collected clinical data of cancer patients at Guy’s and St Thomas’ NHS Foundation Trust (GSTT)
Funding Statement
This project was made possible by funding from the GSTT Cancer Fund
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
beth.russell{at}kcl.ac.uk, charlotte.moss{at}kcl.ac.uk, sophie.papa{at}kcl.ac.uk, sheeba.irshad{at}kcl.ac.uk, paul.ross{at}gstt.nhs.uk, james.spiecer{at}kcl.ac.uk, shahram.kordasti{at}kcl.ac.uk, Danielle.crawley{at}kcl.ac.uk, harriet.wylie{at}kcl.ac.uk, fidelma.cahill{at}kcl.ac.uk, anna.haire{at}kcl.ac.uk, kamarul.zaki{at}gstt.nhs.uk, fareen.rahman{at}gstt.nhs.uk, ailsa.lumsden{at}gstt.nhs.uk, debra.josephs{at}kcl.ac.uk, claire.harrison{at}gstt.nhs.uk, anna.rigg{at}gstt.nhs.uk, Richard.sullivan{at}kcl.ac.uk, Saoirse.dolly{at}gstt.nhs.uk, mieke.vanhemelrijck{at}kcl.ac.uk
Data Availability
Data can be requested by contacting charlotte.moss{at}kcl.ac.uk